David has twenty years of translational science and executive leadership experience in gene therapy and rare disease drug development, with deep expertise in AAV biology, immunogenicity, and IND-enabling program strategy. Most recently, David served as Chief Development Officer at SpliceBio (Barcelona), where he advanced the company's lead dual-AAV gene therapy program for Stargardt disease toward Phase 1/2 clinical development and expanded its Protein Trans-Splicing platform indications, and as Chief Scientific Officer at InnoSkel (France), leading the development of a novel in vivo lentiviral vector-based gene therapy for rare skeletal dysplasia. David was previously Vice President of Translational Medicine at Asklepios Biopharmaceutical (AskBio), where he built the Translational Medicine department and co-led portfolio governance for AAV gene therapy programs in Pompe disease, methyl malonic acidemia (MMA), Limb-Girdle Muscular Dystrophy (LGMD), and congestive heart failure — contributing to the company's $4 billion acquisition by Bayer in 2020. Earlier, as Director of HIV Biology at GlaxoSmithKline (GSK), David led more than 10 drug discovery programs in immunotherapy and curative medicine and co-orchestrated a $20 million public-private HIV Cure Center at the University of North Carolina at Chapel Hill. David joined Kinea Bio to help develop more effective therapeutics for hard-to-cure neuromuscular diseases such as Duchenne muscular dystrophy, Facioscapulohumeral dysplasia (FSHD) and LGMD.